Collegium Pharmaceutical to acquire Corium's ADHD drug for up to $785 million

Collegium Pharmaceutical

19/03/2026 13:11

March 19 (Reuters) - Collegium Pharmaceutical COLL.O on Thursday said it will buy an attention deficit hyperactivity disorder drug from privately held Corium Therapeutics for up to $785 million, expanding its portfolio of ADHD treatments.

Collegium said it will buy the drug, called Azstarys, for $650 million in cash and may pay Corium up to $135 million more, contingent on certain milestones.

Collegium's portfolio already includes another ADHD drug called Jornay PM.

Azstarys treats ADHD in people six years and older, with the capsule combining a fast-acting and a long-acting stimulant in one dose, the company said.

Collegium expects Azstarys to bring in over $50 million in net revenue in the second half of 2026.

Most U.S. patents supporting the product run through December 2037, according to the company.

Collegium will fund the purchase with cash on hand and $300 million it plans to borrow under an existing loan facility.

The deal is expected to close in the second quarter of 2026 and will be immediately accretive to adjusted core profit, the company said.

(Reporting by Sahil Pandey in Bengaluru; Editing by Jonathan Ananda)

((Sahil.Pandey@thomsonreuters.com;))